Stocks and Investing
Stocks and Investing
Tue, November 23, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mani Foroohar Maintained (ARWR) at Hold with Increased Target to $45 on, Nov 23rd, 2021
Mani Foroohar of SVB Leerink, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Hold with Increased Target from $44 to $45 on, Nov 23rd, 2021.
Mani has made no other calls on ARWR in the last 4 months.
There are 2 other peers that have a rating on ARWR. Out of the 2 peers that are also analyzing ARWR, 0 agree with Mani's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Mani
- Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $100 on, Tuesday, August 10th, 2021
- Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Decreased Target to $94 on, Friday, August 6th, 2021
Contributing Sources